Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Cancer Medicine|November 13, 2019
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)Ben Tran, Jose M Ruiz-Morales, Enrique Gonzalez-Billalabeitia, et al.
The Journal of Clinical Investigation|November 19, 2024
Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in miceKatherine L Morel, Beatriz Germán, Anis A Hamid, et al.
Cancer|April 15, 2023
A novel prostate cancer subtyping classifier based on luminal and basal phenotypesAdam B Weiner, Yang Liu, Alex Hakansson, et al.
European Urology Focus|October 9, 2020
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line ChemotherapyChristian Daniel Fankhauser, Ben Tran, Manuel Pedregal, et al.
JAMA Oncology|January 25, 2019
Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell TumorsSaud H AlDubayan, Louise C Pyle, Marija Gamulin, et al.
Genome Medicine|September 4, 2022
Accumulation of copy number alterations and clinical progression across advanced prostate cancerEmily Grist, Stefanie Friedrich, Christopher Brawley, et al.
Nature Cancer|April 26, 2021
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancerKatherine L Morel, Anjali V Sheahan, Deborah L Burkhart, et al.
Cell|August 27, 2025
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancersEmily Grist, Peter Dutey-Magni, Marina A Parry, et al.
Research Square|February 17, 2023
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trialMarina A Parry, Emily Grist, Larissa Mendes, et al.
Pageof 3